KOL | Arlene A ForastiereDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA | Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. | Johns ... |
KOL Resume for Arlene A Forastiere
| Year | |
|---|---|
| 2022 | Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA |
| 2021 | Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. Johns Hopkins University, United States. |
| 2020 | Department of Oncology, Johns Hopkins University, Baltimore, MD, USA |
| 2019 | Johns Hopkins University, Baltimore, MD. |
| 2018 | Johns Hopkins University, Baltimore, Maryland, USA NantHealth, Philadelphia, Pennsylvania |
| 2017 | Harry Quon and Arlene Forastiere, Johns Hopkins University School of Medicine, Baltimore, MD; Neha Vapiwala, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; David J. Adelstein, Taussig Cancer Institute, Cleveland, OH; Holly Boykin, Head and Neck Cancer Alliance, Charleston, SC; Joseph A. Califano, University of California San Diego Medical Center, San Diego; F. Chris Holsinger, Stanford University Medical Center, Palo Alto, CA; Brian Nussenbaum, Washington University School of Medicine, St. Louis, MO; David I. Rosenthal, The University of Texas MD Anderson Cancer Center, Houston TX; and Lillian L. Siu and John N. Waldron, Princess Margaret Cancer Centre, Toronto, Canada. Arlene A. Forastiere, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Jan S. Lewin and Randy Weber, The University of Texas MD Anderson Cancer Center, Houston, TX; Cherie Ann Nathan, LSU Health, Shreveport, LA; David J. Adelstein, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Avraham Eisbruch and Gregory T. Wolf, University of Michigan, Ann Arbor, MI; Gail Fass, Support for People With Oral Head and Neck Cancer, Locust Valley; Bernard O'Malley, Snehal Patel, and David G. Pfister, Memorial Sloan Kettering Cancer Center; Anthony F. Provenzano, New York-Presbyterian Lawrence Hospital, New York, NY; Susan G. Fisher, Temple University; Gregory S. Weinstein, University of Pennsylvania School of Medicine, Philadelphia, PA; Scott A. Laurie, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Quynh-Thu Le, Stanford University, Stanford, CA; and William M. Mendenhall, University of Florida, Gainesville, FL. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Department of Oncology Baltimore Maryland Johns Hopkins University, Baltimore MD; American Society of Clinical Oncology, Alexandria VA; and University of Michigan Hospital, Ann Arbor, MI. |
| 2016 | Department of Oncology, Johns Hopkins University and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD |
| 2015 | Arlene A. Forastiere, Johns Hopkins University and Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Randal S. Weber, The University of Texas MD Anderson Cancer Center, Houston, TX; and Andy Trotti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; and eviti, Philadelphia, PA. Johns Hopkins Univ School of Medcn, Baltimore, MD |
| 2014 | Department of Medical Oncology, Johns Hopkins University, Baltimore |
| 2013 | Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH Dana-Farber Cancer Institute, Boston, MA Eviti, Inc., Philadelphia, PA |
| 2012 | The Johns Hopkins University, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Bronx, NY; Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Johns Hopkins University School of Medicine, Baltimore, Maryland Massachusetts Eye and Ear Infirmary, Boston, MA eviti, Philadelphia, PA |
| 2011 | and Exelixis, South San Francisco, CA. Johns Hopkins University, Baltimore, MD Sidney Kimmel Comprehensive Cancer Center University of Chicago, Chicago, IL |
| 2010 | Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA |
| 2009 | Affiliations of authors: Department of Oncology, Johns Hopkins University, School of Medicine, Sidney Kimmel Cancer Center, Baltimore, MD (AAF); Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL (AMT) Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland Johns Hopkins University School of Medicine, Baltimore, MD, USA Head and Neck Section, Fox Chase Cancer Center |
Arlene A Forastiere: Influence Statistics
| Concept | World rank |
|---|---|
| wound fistula | #1 |
| radiation ccr | #1 |
| assignment larger density | #1 |
| hpv neck scientific | #1 |
| singleinstitution pilot trials | #1 |
| hospitalization hospital cost | #1 |
| total glossectomy mandibulectomy | #1 |
| 1 epithelial tumors | #1 |
| krasvariant genotyping | #1 |
| baseline gefitinib | #1 |
| grade 2 myelosuppression | #1 |
| singlemodality surgery | #1 |
| courses median courses | #1 |
| costs nonoperative treatment | #1 |
| nmf dose schedule | #1 |
| e5397 randomized trial | #1 |
| cycles concurrent paclitaxel | #1 |
| scientific discovery standards | #1 |
| common definitions metrics | #1 |
| tne esophagus categories | #1 |
| 2 operative morbidity | #1 |
| 56 65 months | #1 |
| early localregional recurrence | #1 |
| careful modeling techniques | #1 |
| arm 65 months | #1 |
| taxane inclusion | #1 |
| adequate physiological indices | #1 |
| ixabepilone scchn | #1 |
| multimodality treatment response | #1 |
| arm preoperative chemoradiation | #1 |
| fiftyseven courses | #1 |
| carboplatin 5fu | #1 |
| docetaxel irinotecan combination | #1 |
| neck scientific groupwww | #1 |
| toxic larynx preservation | #1 |
| biological agents interventions | #1 |
| mmp inhibitor prinomastat | #1 |
| total qes | #1 |
| respiratory complications 32 | #1 |
| 20 daily radiation | #1 |
| 60 disease progression | #1 |
| standard organ preservation | #1 |
| settings promising | #1 |
| phase trials acma | #1 |
| median survial time | #1 |
| quantitative endoscopy qe | #1 |
| surgical salvage surgery | #1 |
| 177 subsequent weeks | #1 |
| mtcenriched cohort | #1 |
| increase neck dissection | #1 |
Open the FULL List in Excel | |
Prominent publications by Arlene A Forastiere
BACKGROUND: Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SCCHN). We assessed the efficacy and safety of panitumumab combined with cisplatin and fluorouracil as first-line treatment for these patients.
METHODS: This open-label phase 3 randomised trial was done at 126 sites in 26 countries. Eligible patients were aged at least 18 years; had histologically ...
| Known for Panitumumab Patients | Metastatic Squamous | P16 Status | Cell Carcinoma | Label Phase |
Improved Survival of Patients With Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
[ PUBLICATION ]
BACKGROUND: The improved prognosis for patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) relative to HPV-negative HNSCC observed in retrospective analyses remains to be confirmed in a prospective clinical trial.
METHODS: We prospectively evaluated the association of tumor HPV status with therapeutic response and survival among 96 patients with stage III or IV HNSCC of the oropharynx or larynx who participated in an Eastern Cooperative ...
| Known for Human Papillomavirus | Patients Hnscc | Positive Head | Cell Carcinoma | Prospective Clinical Trial |
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
[ PUBLICATION ]
BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown.
METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with ...
| Known for Concurrent Chemotherapy | Cisplatin Radiotherapy | Laryngeal Cancer | Organ Preservation | Locoregional Control |
The gene that encodes methylthioadenosine phosphorylase (MTAP), an enzyme involved in adenine and methionine salvage pathways, is located on chromosome 9p21 telomeric to the p16INK4A/CDKN2A tumor suppressor gene. Inactivation of the p16INK4A/CDKN2A gene occurs by three different mechanisms: hypermethylation of the gene promoter, intragenic mutation coupled with loss of the second allele, and homozygous deletion. Immunohistochemical labeling for the p16INK4A/CDKN2A gene product parallels ...
| Known for Homozygous Deletion | Loss Mtap | Gastric Adenocarcinoma | P16 Cdkn2a | Esophageal Neoplasms |
Genetic Alterations in Barrett Esophagus and Adenocarcinomas of the Esophagus and Esophagogastric Junction Region
[ PUBLICATION ]
The incidence of esophageal adenocarcinoma has increased markedly in the past two decades, but the genetic alterations in this cancer and its precursor, Barrett mucosa, have not been characterized extensively. DNA replication errors and allelic losses of chromosomes 17p, 18q, and 5q were studied in 36 resected adenocarcinomas arising in the esophagus and esophagogastric junction, 56 Barrett adenocarcinomas, and 11 dysplasias in Barrett esophagus. The results were compared with clinical ...
| Known for Genetic Alterations | Barrett Esophagus | Esophagogastric Junction | Loss 18q | Esophageal Adenocarcinoma |
Association between Cigarette Smoking and Mutation of the p53 Gene in Squamous-Cell Carcinoma of the Head and Neck
[ PUBLICATION ]
BACKGROUND: Although epidemiologic studies have long associated tobacco and alcohol use with the development of squamous-cell carcinoma of the head and neck, the molecular targets of these carcinogens have yet to be identified. We performed a molecular analysis to determine the pattern of mutations in the p53 gene in neoplasms from patients with squamous-cell carcinoma of the head and neck and a history of tobacco or alcohol use.
METHODS: Sequence analysis of the conserved regions of the ...
| Known for Cigarette Smoking | P53 Gene | Cell Carcinoma | Head Neck | Mutations Patients |
PURPOSE: Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months. These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS.
PATIENTS AND METHODS: Patients with recurrent/metastatic squamous cell carcinoma of the head and neck were randomly assigned to receive cisplatin every 4 weeks, ...
| Known for Cisplatin Cetuximab | Patients Egfr | Recurrent Head | Monoclonal Antibodies | Neck Cancer |
BACKGROUND: The abrogation of function of the tumor-suppressor protein p53 as a result of mutation of its gene, TP53, is one of the most common genetic alterations in cancer cells. We evaluated TP53 mutations and survival in patients with squamous-cell carcinoma of the head and neck.
METHODS: A total of 560 patients with squamous-cell carcinoma of the head and neck who were treated surgically with curative intent were enrolled in our prospective multicenter, 7-year study. TP53 mutations ...
| Known for Tp53 Mutations | Hazard Ratio | Cell Carcinoma | Head Neck | Decreased Survival |
PURPOSE: To investigate the feasibility of combining concomitant boost accelerated radiation regimen (AFX-C) with cisplatin and to assess its toxicity and the relapse pattern and survival in patients with advanced head and neck carcinoma (HNC).
PATIENTS AND METHODS: Between April and November of 2000, 84 patients with stage III to IV HNC who met the eligibility criteria were enrolled; 76 of these patients were analyzable. Radiation consisted of 72 Gy in 42 fractions over 6 weeks (daily ...
| Known for Advanced Head | Neck Carcinomas | Concomitant Boost | Radiation Therapy | Concurrent Cisplatin |
p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell Carcinoma
[ PUBLICATION ]
BACKGROUND: The p53 gene (also known as TP53) may be the most common genetic target involved in the malignant transformation of human cells. Direct sequence analysis has demonstrated that alteration of this gene occurs in approximately 45% of head and neck squamous cell carcinomas. The consequences of p53 mutations in these cancers with respect to tumor behavior and patient survival have not been rigorously determined.
PURPOSE: We evaluated the implications of p53 mutations in relation ...
| Known for P53 Mutation | Neck Squamous | Radiation Therapy | Treatment Failure | Tumor Stage |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
[ PUBLICATION ]
PURPOSE: A pilot study of 43 patients with potentially resectable esophageal carcinoma treated with an intensive regimen of preoperative chemoradiation with cisplatin, fluorouracil, and vinblastine before surgery showed a median survival of 29 months in comparison with the 12-month median survival of 100 historical controls treated with surgery alone at the same institution. We designed a randomized trial to compare survival for patients treated with this preoperative chemoradiation ...
| Known for Preoperative Chemoradiation | Esophageal Carcinoma | Surgery Arm | Cisplatin Fluorouracil | Survival 1 |
Key People For Neck Cancer
Arlene A Forastiere:Expert Impact
Concepts for whichArlene A Forastierehas direct influence:Neck cancer, Squamous cell, Radiation therapy, Head neck, Esophageal cancer, Cell carcinoma, Esophageal adenocarcinoma, Induction chemotherapy.
Arlene A Forastiere:KOL impact
Concepts related to the work of other authors for whichfor which Arlene A Forastiere has influence:Squamous cell, Neck cancer, Human papillomavirus, Nasopharyngeal carcinoma, Induction chemotherapy, Radiation therapy, Oral cavity.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |